{"DataElement":{"publicId":"6581907","version":"1","preferredName":"Liver Cancer AJCC Edition 8 Pathologic Distant Metastasis M Category","preferredDefinition":"Extent of the distant metastasis for hepatocellular carcinoma and fibrolamellar carcinoma based on clinical stage information combined with operative findings, and evidence obtained from pathology review when surgery is the first definitive therapy, using AJCC Ed. 8 criteria.","longName":"LIVR_AJC8_PTH_M_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3179802","version":"1","preferredName":"Liver Cancer Pathologic M Stage","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation._Pathologic; caused by or altered by or manifesting disease or pathology._One criteria of the TMN staging system.  M refers to the presence of metastasis.","longName":"2834593v1.0:2207807v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2834593","version":"1","preferredName":"Hepatocellular Carcinoma","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","longName":"C3099","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62421A44-5466-782E-E040-BB89AD437669","latestVersionIndicator":"Yes","beginDate":"2009-02-06","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2009-02-06","modifiedBy":"ONEDATA","dateModified":"2009-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207807","version":"1","preferredName":"Pathologic M Stage","preferredDefinition":"Pathologic; caused by or altered by or manifesting disease or pathology.:One criteria of the TMN staging system.  M refers to the presence of metastasis.","longName":"C25610:C25727","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-30F5-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"98F4C330-5E31-4FA5-E040-BB89AD434222","latestVersionIndicator":"Yes","beginDate":"2011-01-03","endDate":null,"createdBy":"WHITES","dateCreated":"2011-01-03","modifiedBy":"TAYLORT","dateModified":"2018-12-19","changeDescription":"12/19/18 TT transferred ownership from NCIP to NCI Standards. Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6580738","version":"1","preferredName":"Hepatocellular Carcinoma American Joint Committee on Cancer Edition 8 M Category","preferredDefinition":"A finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._One criteria of the TNM staging system. M refers to the presence of metastasis._A grouping of items based on some commonality or by user defined characteristics.","longName":"6580738v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"3","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"pM1","valueDescription":"Hepatocellular Carcinoma pM1 TNM Finding v8","ValueMeaning":{"publicId":"6580740","version":"1","preferredName":"Hepatocellular Carcinoma pM1 TNM Finding v8","longName":"6580740","preferredDefinition":"Hepatocellular carcinoma with distant metastasis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma pM1 TNM Finding v8","conceptCode":"C134467","definition":"Hepatocellular carcinoma with distant metastasis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5CD369-8ED6-5DA5-E053-F662850A598F","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5CD369-8EEF-5DA5-E053-F662850A598F","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"cM1","valueDescription":"Hepatocellular Carcinoma cM1 TNM Finding v8","ValueMeaning":{"publicId":"6580742","version":"1","preferredName":"Hepatocellular Carcinoma cM1 TNM Finding v8","longName":"6580742","preferredDefinition":"Hepatocellular carcinoma with distant metastasis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma cM1 TNM Finding v8","conceptCode":"C134462","definition":"Hepatocellular carcinoma with distant metastasis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5CD369-8EFC-5DA5-E053-F662850A598F","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5CD369-8F15-5DA5-E053-F662850A598F","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"},{"value":"cM0","valueDescription":"Hepatocellular Carcinoma cM0 TNM Finding v8","ValueMeaning":{"publicId":"6580744","version":"1","preferredName":"Hepatocellular Carcinoma cM0 TNM Finding v8","longName":"6580744","preferredDefinition":"Hepatocellular carcinoma without evidence of distant metastasis. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma cM0 TNM Finding v8","conceptCode":"C134461","definition":"Hepatocellular carcinoma without evidence of distant metastasis. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5CD369-8F22-5DA5-E053-F662850A598F","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7C5CD369-8F3B-5DA5-E053-F662850A598F","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6580737","version":"1","preferredName":"Hepatocellular Carcinoma TNM Finding v8 American Joint Committee on Cancer M Category Category","preferredDefinition":"A finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.):A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:One criteria of the TNM staging system. M refers to the presence of metastasis.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C134457:C39315:C25727:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma TNM Finding v8","conceptCode":"C134457","definition":"A finding about one or more characteristics of hepatocellular carcinoma, following the rules of the TNM AJCC v8 classification system. This staging system applies to hepatocellular carcinomas and fibrolamellar carcinomas (fibrolamellar variant of hepatocellular carcinoma). Intrahepatic cholangiocarcinomas, combined hepatocellular-cholangiocarcinomas, and sarcomas of the liver are not staged using this staging system. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C5CD369-8EA9-5DA5-E053-F662850A598F","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"ONEDATA","dateModified":"2018-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7C5CD369-8EBA-5DA5-E053-F662850A598F","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"TAYLORT","dateModified":"2019-08-30","changeDescription":"8-20-19 released per MC.; 12/6/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000438","version":"1","longName":"Liver","context":"NCI Standards"},{"publicId":"6005920","version":"1","longName":"AJCC Edition 8","context":"NCI Standards"}]},{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6776762","version":"1","longName":"Bile duct and Liver","context":"OCCPR"},{"publicId":"6779541","version":"1","longName":"LIHC Baseline","context":"OCCPR"}]}],"AlternateNames":[{"name":"OCCPR","type":"USED_BY","context":"OCCPR"}],"ReferenceDocuments":[{"name":"Pathologic M category","type":"Preferred Question Text","description":"Pathologic M category","url":null,"context":"NCI Standards"},{"name":"CPTAC-BSLN-1","type":"Alternate Question Text","description":"Pathologic Distant Metastasis Status (pM)","url":null,"context":"OCCPR"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7C6092E0-0008-486A-E053-F662850AD7D0","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-12-06","modifiedBy":"KNABLEJ","dateModified":"2020-02-14","changeDescription":"8-30-19 TMT released per MC.; 12/6/18 tmt created for standardization.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}